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Abstract
Background—Dementia and mild cognitive impairment (MCI) are under-recognized in community settings.
This may be due in part to the lack of brief dementia screening tools available to clinicians. We compared two
brief, informant-based screening tests: the AD8 and the Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE) in a community-based neurology practice in the Midwestern United States
Methods—We examined 186 consecutive patients (44 controls, 13 with MCI, and 129 with dementia).
Receiver operator characteristic curves were used to examine the ability of AD8 and IQCODE to discriminate
between controls and MCI or dementia. Sensitivity, specificity, predictive values, and likelihood ratios were
reported. Results—AD8 differentiated healthy controls from MCI (p
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Abstract
Background—Dementia and mild cognitive impairment (MCI) are under-recognized in
community settings. This may be due in part to the lack of brief dementia screening tools available
to clinicians. We compared two brief, informant-based screening tests: the AD8 and the Informant
Questionnaire on Cognitive Decline in the Elderly (IQCODE) in a community-based neurology
practice in the Midwestern United States
Methods—We examined 186 consecutive patients (44 controls, 13 with MCI, and 129 with
dementia). Receiver operator characteristic curves were used to examine the ability of AD8 and
IQCODE to discriminate between controls and MCI or dementia. Sensitivity, specificity,
predictive values, and likelihood ratios were reported.
Results—AD8 differentiated healthy controls from MCI (p<.001) or dementia (p<.001), as well
as MCI from dementia (p=.008). The IQCODE differentiated controls and MCI from dementia
(both p<.001), and between controls and MCI (p=.002). Both AD8 (AUC = 0.953, 95% CI: 0.92–
0.99) and IQCODE (AUC = 0.930, 95% CI: 0.88–0.97) provided discrimination between controls
and patients with dementia; however the AD8 had superior sensitivity detecting dementia (99.2%)
and MCI (100%) compared to the IQCODE (79.1% for dementia, 46.1% for MCI) with non-
overlapping confidence intervals. Using published cut-offs (AD8 ≥ 2, IQCODE ≥ 3.4), only one
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case of dementia was missed with the AD8 while the IQCODE failed to detect dementia in 27
individuals. The AD8 detected MCI in all 13 individuals while the IQCODE misclassified 7
individuals.
Conclusion—Both the AD8 and IQCODE were able to detect dementia in a community setting.
The AD8, however, was more successful than IQCODE in detecting MCI. If simple and efficient
screening for early cognitive impairment is the goal, particularly in the early stages (e.g., for
prevention trials or public screening), the combination of an informant interview (the AD8) and a
brief performance measure could be considered as they meet the basic requirements of the
Personalized Prevention Plan for Medicare beneficiaries.
Keywords
Dementia; Screening; AD8; IQCODE; Mild Cognitive Impairment
INTRODUCTION
Despite the benefits of early detection, including effective treatment of the disease and its
complications and enabling the patient (and family) to prepare for the future, dementia is
still under-recognized in the community.1,2 This is in part due to dismissal by patients and
families of early signs of the disease as normal aging, denial, lack of time in a busy clinical
practice and the lack of time-sensitive, effective screening tools.3 Given the brief time
available to primary care physicians in a standard office visit, sensitive and specific
cognitive impairment screening tools that are valid, easy to administer, and minimally time
consuming are needed.4,5
The screening for and assessment of cognitive impairment and dementia has traditionally
been carried out by comparing individual performance on cognitive test measures with
normative values.6–8 However, since the diagnosis of Alzheimer disease (AD) and related
dementias is founded on intra-individual decline in cognition with interference in
accustomed daily activities, a complement to the conventional approach to dementia
screening, (i.e., comparing cognitive function to normative values), is to assess cognitive
change in an individual.5,9–11 In assessing cognitive change it is necessary to have estimates
of both current and pre-morbid levels of ability. Assessment of current cognitive ability
poses little problem, but records of pre-morbid ability are rarely available. A possible
solution to the problem of estimating cognitive decline is to use informants who have
knowledge of both the subject’s current and pre-morbid behavior.12,13 The informant is
usually asked to rate change over a period of time from earlier in life (i.e., reported intra-
individual change). Informant reports permit the use of patients as their own controls while
eliminating the need for baseline assessments.5,9 Moreover, assessing cognitive decline,
rather than current functioning, does not require accounting for the level of education, pre-
morbid intelligence and cultural differences. Other advantages of informant questionnaires
are: relevance to everyday life, greater cross-cultural portability, applicability to people with
limited education, less threat to the self-esteem of the person assessed, and the possibility of
assessment by mail or telephone.12,13 The main disadvantage of informant interviews has
been that they have been time consuming. The Gold Standard for informant assessments, the
Clinical Dementia Rating (CDR)14 can take 45–60 minutes to complete and thus is not
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practical in a typical clinical office visit. Therefore, more recently, there has been an effort
to develop brief informant interviews to gauge intra-individual change.
Two commonly used informant questionnaires are the AD85,9–11 and the Informant
Questionnaire on Cognitive Decline in the Elderly (IQCODE).15–17 Both were developed
and validated as part of longitudinal studies of memory and aging to assess the presence of
dementia. The AD8 has 8 yes/no questions and takes 2–3 minutes to complete.9 The
IQCODE has 16 items scored on a 5-point Likert scale and takes 5–7 minutes to complete.15
Both the AD8 and IQCODE can be self-administered by the informant without the
assistance of medical or office staff. Because of the ease of use for dementia screening, they
could prove useful for future public health initiatives. In this study, we compared the
IQCODE and the AD8 as screening tools for dementia and mild cognitive impairment
(MCI)18 in a community-based practice.
METHODS
Clinical Data
A total of 219 consecutive patients visiting a community-based Neurology/Memory Clinic
in the Midwestern United States were asked to participate. As the purpose of this study was
to investigate two informant-based dementia screening tests to detect dementia and MCI in a
community setting, 33 patients with co-morbid medical conditions (e.g., sleep apnea,
alcoholism, schizophrenia) that could potentially affect cognition but were not dementias
were excluded from these analyses. Neither the AD8 nor IQCODE have been studied in
these populations. The majority were patients seen in a Memory Clinic (N = 152), while
additional controls (N = 34) were individuals without memory complaints seen in the setting
of a General Neurology clinic for a final sample size of 186. Clinical data were collected
between August 2006 and October 2008 and assessments were performed by one Board-
Certified behavioral neurologist (MR) throughout the study. The majority of informants
were adult children and/or spouses.
Informant Ratings of Cognitive Status
The AD85 and IQCODE were independently completed by the informant, and the study
clinicians were blinded to the scores. The AD8 gauges the informant’s perception of the
target’s problems in the areas of memory, problem-solving abilities, orientation, and daily
activities due to cognitive changes over the last “several years.” The AD8 is comprised of 8
items and respondents indicate their endorsement as Yes (1) or No (0). Items are summed
resulting in a possible range of 0 – 8. The suggested cut-off score for dementia is 2 or
greater.5,9–11 The AD8 is highly correlated with Gold Standard evaluations including the
CDR14 and neuropsychological testing9 and with imaging and cerebrospinal fluid (CSF)
biomarkers of AD.19
The second informant measure was the IQCODE.15–17 Informants rate the target’s cognitive
change compared to 10 years prior. The IQCODE is comprised of 16 items representing
everyday “situations where this person has to use his/her memory or intelligence.”
Respondents use a 5-point Likert scale to indicate the degree of change (1 = Much Improved
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to 5 = Much Worse) compared to ten years prior. A total score is derived by calculating the
average of completed items. The cut-off for dementia suggested in the literature ranges from
3.4 – 3.9.17
Cognitive Evaluation
Each patient and informant underwent a detailed history of cognitive and neurological
symptoms and each patient received a comprehensive neurological and cognitive
examination, performed by a single Board-certified Behavioral Neurologist (MR). As part of
this comprehensive assessment, each patient was assessed for cognitive performance with
the Mini-Mental State Examination (MMSE),20 the Clock Draw task,21 a three-word recall
to calculate a Mini-Cog score,22,23 and a category fluency task (Animal Naming).24
Clinical Diagnoses
Individuals with MCI were diagnosed according to published criteria25 and categorized
either as an amnestic or non-amnestic form based on the presence of memory impairment
demonstrated by patient performance on testing and interviews with the patient and
informant. Diagnoses of AD26, Lewy body dementia (LBD)27, vascular dementia (VaD)28
and frontotemporal dementia (FTLD)29 were made according to published criteria at the
time of project initiation. Individuals were considered to have mixed dementia if they met
criteria for two or more neurodegenerative disorders. Cognitively normal controls were
recruited from a general neurology clinic and did not meet criteria for MCI or dementia. The
AD8 and IQCODE were not used in establishing the clinical diagnosis.
Statistical Analyses
All analyses were conducted using SAS v9.3 (SAS Institute Inc., Cary, NC). Descriptive
statistics were used to characterize and compare groups. Given the ordinal scale on which
our different concepts were measured, we used non-parametric methods to compare the
three diagnostic groups including Kruskal-Wallis tests for overall differences and post-hoc
Wilcoxon rank-sum tests to test for specific differences (e.g., control vs. MCI). Regression
analysis with estimate statements was used to obtain overall and specific group differences
in means, while differences in proportions were tested with the chi-square test for overall
differences and with the Marascuilo test30 for specific comparisons. Spearman’s rho
correlations were used to examine strength of associations between informant and
performance measures. Sensitivity, specificity, positive and negative predictive values are
reported. Receiver operator characteristic (ROC) curves and the area under the ROC curve
(AUC) were generated to reflect graphically and quantitatively the ability of the AD8 and
IQCODE to discriminate between cognitively normal patients and patients with dementia.
Analyses were repeated to determine discriminative properties of the AD8 and IQCODE
between cognitively normal patients and patients with MCI. Although nonparametric
methods to estimate AUC are available, an underestimation compared to parametric AUC
estimates has been reported particularly in the case of discrete (e.g., ordinal) data.31 We
examined this by using Wilcoxon rank-sum statistics to calculate AUC to exclude the
possibility that nonparametric methods would lead to significantly different AUC estimates.
The following formulas were used to obtain 95% CI around the nonparametric AUC
estimates:
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Another way to evaluate the utility of screening tests is with the likelihood ratio.19,32 The
likelihood ratio of any screening test is the probability that a positive test is found in persons
with disease divided by the probability of the same finding in persons without disease.32
Likelihood ratios range from 0 to infinity with larger numbers providing more convincing
evidence of disease; smaller numbers argue the disease is less likely; ratios close to 1 lack
diagnostic value. Positive likelihood ratios greater than 5 or negative likelihood ratios less
than 0.2 increase the probability of disease. Likelihood ratios were computed for both AD8
and IQCODE.
RESULTS
Participant Characteristics
Participant characteristics by group are summarized in Table 1. The sample consisted of 186
participants. The mean age of the patients was 77.8±8.2y with 13.2±2.9y of education. The
cohort was 67% female and 38% were married with a mean MMSE score of 24.8±4.4.
Clinical diagnoses for the group were 44 Controls, 13 MCI (10 amnestic, 3 non-amnestic),
and 129 Dementia (64 AD, 40 mixed AD/VaD, 13 VaD, 10 LBD, 2 FTLD). Individuals
with dementia diagnoses were rated as mild (69.8%), moderate (29.5%) or severe (0.8%).
As expected, MMSE and Mini-Cog scores significantly differed across groups and were
highest in the controls and lowest in the dementia group. However, Animal Naming and
Clock Drawing were not able to capture differences between MCI and controls (p=0.85 and
p=0.06, respectively).
Informant Ratings
AD8 and IQCODE scores differed significantly between the three comparison groups
(overall and specific comparisons (Table 1). Both the AD8 and the IQCODE were correlated
with all performance measures (all p-values <.001, Table 2).
Discriminating Cognitively Normal Individuals from Dementia
We next examined the ability of the two informant scales to correctly classify individuals’
clinical diagnoses (Table 3). ROC curves were generated to measure the properties of the
AD8 and IQCODE in classifying cognitively normal control individuals from those with
dementia. Both the AD8 (AUC = 0.953, 95% CI: 0.92–0.99) and the IQCODE (AUC =
0.930, 95% CI: 0.88–0.97) discriminated dementia from no dementia. Although smaller, the
non-parametric estimates showed similar trends as found using the parametric method
(dementia vs. controls: AUCAD8=0.883 (95% CI: 0.833–0.933) and AUCIQCODE=0.839
(95% CI: 0.779–0.899). The AD8 had superior sensitivity (99.2%, 95% CI: 95.7–99.8) for
the presence of dementia compared with IQCODE (79.1%, 95% CI: 71.3–85.2) with non-
overlapping confidence intervals. The specificity and positive predictive value (PPV) did not
differ between the AD8 and IQCODE. However the negative predictive value (NPV) of the
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AD8 was superior to the IQCODE (97.1% vs. 59.1% with non-overlapping confidence
intervals). There was no difference in the likelihood ratio of a positive test between the AD8
and IQCODE, however the AD8 had a superior likelihood ratio of a negative test (0.01 vs.
0.24) compared with the IQCODE. Applying the published cut-offs (AD8 ≥ 2, IQCODE ≥
3.4), the AD8 failed to detect dementia in only one individual while the IQCODE failed to
detect dementia in 27 individuals.
Discriminating Cognitively Normal Individuals from MCI
We repeated these analyses by only considering individuals with MCI compared with
cognitively normal older adults (Table 3). Although the sample size is small (n=13) both the
AD8 (AUC = 0.899, 95% CI: 0.82–0.98) and IQCODE (AUC = 0.772, 95% CI: 0.61–0.94)
discriminated cognitively normal individuals from those with MCI. Similarly to the normal-
dementia comparison, the non-parametric AUC estimates were slightly lower but showing
the same trend (AUCAD8=0.886 (95% CI: 0.760–1.012 and AUCIQCODE=0.674 (95% CI:
0.494–0.854). There were no differences in sensitivity, specificity, PPV, NPV or likelihood
ratio of a positive test between AD8 and IQCODE for detecting MCI, however the
likelihood ratio of a negative test favored the AD8 (0 vs. 0.6). Applying the published cut-
offs (2 and 3.4), AD8 detected MCI in all 13 individuals whereas the IQCODE failed to
detect MCI in 7 individuals.
DISCUSSION
Using brief informant interviews enabled us to detect dementia and MCI at the earliest
stages by placing emphasis on reported intra-individual decline, rather than inter-individual
comparisons of performance according to published norms.9 We found that two brief
informant rating systems, the AD8 and IQCODE were able to detect the presence of
cognitive impairment in community settings and were highly correlated with brief
assessments of cognitive ability (MMSE, Mini-Cog, Clock Drawing, and Animal Naming)
that are commonly used in community settings. Informants (spouses, adult children) using
the AD8 were able to identify all but one individual with cognitive impairment. Using the
IQCODE, informants were less successful in identifying individuals with cognitive
impairment, characterizing 34 individuals with MCI or dementia as having no impairment.
The false positive rates for the AD8 and IQCODE were not different.
Cognitive impairment due to dementia or MCI is under-recognized in the community.1,2
There are a number of reasons this may be true, but at least part of the cause may be due to
the lack of brief measures that can discriminate normal aging from very mild impairments in
a time-effective manner. A number of brief performance-based dementia screening measures
(e.g., the MMSE20) are already in use, but may be (1) unable to detect or quantify change
from previous levels of function; (2) insensitive to subtle changes in high functioning
individuals (i.e., ceiling effects) who may score well within the normal range throughout the
early stages of dementia; (3) unable to discern decline in individuals with poorer lifelong
abilities; and (4) culturally insensitive thereby underestimating abilities of African
Americans and other minority groups.33,34 Informant assessments such as the AD8 are
without ceiling effects and valid in assessing individuals regardless of age, gender, language,
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race or educational level.2,5,9–11 The National Guideline Clearinghouse35 recommends the
combined use of an informant interview with a performance measurement to detect
dementia and we have previously demonstrated that combining the AD8 with brief tests
improve detection of cognitive impairment.11 It is also important to consider whether
patients are willing to be screened for dementia. Studies have reported a willingness of
patients to be screened if there are perceived benefits to being screened and if the clinician
can offer treatments for problems when detected.36,37
The goal of any screening test is to separate people with a high probability of having the
disease from those with a low probability. An effective screening test for dementia should be
socially acceptable, safe, inexpensive, reliable, sensitive, specific, and brief. Gold standard
informant interviews such as the Clinical Dementia Rating are not practical in a community
setting – hence the need to develop and validate brief informant interviews – both the AD8
and IQCODE fulfill these criteria. The AD8 and IQCODE are highly correlated with
performance on brief objective cognitive measures in common use. Consistent with previous
studies, both the AD8 and IQCODE differentiated cognitively normal from individuals with
dementia.5,9–11,15–17 The AD8, however, was better than IQCODE in detecting MCI which
is consistent with a recent report that also found the IQCODE was not useful in detecting
MCI.38
There are a number of possible reasons for the differences. Although both the AD8 and
IQCODE use informants, the domains assessed differ slightly. While the IQCODE covers
two aspects of memory (acquisition of new information and retrieval of existing knowledge)
and two aspects of intelligence (verbal and performance), the AD8 contains items that relate
to memory, problem-solving abilities, orientation, and daily activities. Another explanation
for why the AD8 may be better than IQCODE in detecting dementia at an earlier stage (i.e.,
MCI) is probably rooted in the history of their development. AD8 was originally developed
from a battery of 56 questions.5 Questions that were very good at discriminating cognitively
normal adults from moderate dementia but did not provide early discrimination were
excluded. Other questions were so often endorsed by cognitively normal adults (forgetting
day and date for example) that they provided little discrimination. The statistical models
were modified to provide discriminations between CDR 0 and CDR 0.5 (that encompass
both very mild dementia and MCI) because this is the dilemma posing most clinicians. This
appears not to have been done (at least not consciously) for IQCODE. Thus, AD8 may be
better at early disease detection precisely because it was fundamentally designed to detect
early disease. Indeed a recent study demonstrated that the degree of functional impairment
as measured by the CDR (which is the basis for development of AD8, but not IQCODE),
predicted which MCI patients converted to clinical dementia.39 Finally the AD8 is highly
correlated with biomarkers of AD including amyloid imaging and cerebrospinal fluid tau
and amyloid β-42.19 These biomarkers are now considered hallmarks for early diagnosis of
Alzheimer disease and MCI and have been incorporated into revised criteria.18,40
Our study has limitations. The sample size of the MCI cohort was small. With a larger
sample size, the confidence intervals may narrow demonstrating statistical differences
between the AD8 and IQCODE. Most, but not all patients underwent commonly used “Gold
Standards” in research centers – the CDR14 for informant interviews or detailed
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neuropsychological tests. However the goal of this study was to demonstrate the utility of
these brief informant interviews in the setting of a community practice where Gold Standard
evaluations are generally not feasible. Our study was initiated before the publication of the
revised criteria for MCI18 and Alzheimer’s disease.40 However, the clinical features are not
sufficiently different between the revised criteria and the previous iterations to affect clinical
diagnosis. We did not collect biomarkers for this study but have previously demonstrated
validation of the AD8 against clinical, neuropsychological and biomarker assessments.9,19
Exclusion criteria for this study included medical conditions such as sleep apnea,
schizophrenia, alcohol or drug use that could cause cognitive impairment but are not
considered dementias. Neither the AD8 nor the IQCODE were designed to explore cognitive
impairment in non-degenerative medical conditions nor are there currently any data to
suggest that they would be able to do so. However the stated goals of this study were to
determine if brief informant screening tools would improve detection of dementia and MCI
in older adults coming to a community-based practice.
Alzheimer’s disease, MCI and related disorders will become a public health crisis and a
severe burden on Medicare in the next two decades unless actions are taken to (1) develop
disease modifying medications, (2) provide clinicians with valid and reliable measures to
detect disease at the earliest possible stage, and (3) reimburse clinicians for their time to
evaluate patients.2 Dementia screening requires a consideration of the population-at-risk and
the sensitivity and specificity of the instruments used.41 A large number of false positive
individuals might expend limited health care dollars; a large number of individuals receiving
false negatives would be denied treatment and miss opportunities to participate in clinical
research. Thus, a staged dementia screening approach would make the most sense clinically
and economically. The value of the AD8 is that it is not only brief but also corresponds to
more detailed evaluations, neuropsychological testing and AD biomarkers,19 an argument
that based on the currently available data, may not apply to the IQCODE. In this report, we
demonstrated the AD8 may be superior to the IQCODE in detecting cognitive impairment at
an earlier stage (i.e. MCI). In the environment of healthcare reform, it will be important for
clinicians to use brief, sensitive and reliable methods to detect cognitive impairment in their
patients. If simple screening for early cognitive impairment in the busy office setting is the
goal the AD8 plus a brief performance measure such as the Mini-Cog22,23 could be
recommended, particularly because they meet the basic requirements of the Personalized
Prevention Plan for Medicare beneficiaries.42
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Table 2
Strength of Association between Informant Ratings and Performance Measures
AD8 IQCODE
IQCODE .831 --
MMSE −.664 −.642
Mini-Cog −.564 −.530
Animal Fluency −.464 −.445
3-word Recall −.548 −.496
Clock Draw −.326 −.350
All p-values <.001 for Spearman’s Rho Coefficients
Key: IQCODE=Informant Questionnaire on Cognitive Decline in the Elderly; MMSE=Mini Mental State Examination
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Table 3
Discriminative Ability and Psychometric Properties of the AD8 and IQCODE
Classification by Clinical Diagnoses
AD8 IQCODE
Not impaired (AD8 <2) Impaired (AD8 ≥2) Not impaired (IQCODE<3.4) Impaired (IQCODE ≥ 3.4)
No impairment 34 10 39 5
MCI 0 13 7 6
Dementia 1 128 27 102
Psychometric Properties
Dementia vs. No Dementia MCI vs. No Dementia
AD8 IQCODE AD8 IQCODE
AUC .953 (.915–.992) .930 (.885–.975) .899 (.821–.978) .772 (.606–.938)
Sensitivity, % 99.2 (95.7–99.8) 79.1 (71.3–85.2) 100 (77.2–100) 46.1 (23.2–70.9)
Specificity, % 77.3 (63.0–87.2) 88.6 (76.0–95.1) 77.3 (63.0–87.2) 88.6 (76.0–95.1)
PPV, % 92.8 (87.2–96.0) 95.3 (89.5–97.9) 56.5 (36.8–74.4) 54.6 (28.0–78.7)
NPV, % 97.1 (85.5–99.5) 59.1 (47.1–70.1) 100 (89.9–100) 84.8–(71.8–92.4)
+ LR 4.4 (3.6–5.3) 6.9 (4.7–10.4) 4.4 (3.6–5.4) 4.1 (1.9–8.8)
− LR 0.01 (0.001–0.07) 0.24 (0.21–0.26) 0 (undefined) 0.6 (0.4–0.8)
Area under the curve (95% confidence interval)
Note: MCI = mild cognitive impairment; IQCODE= Informant Questionnaire on Cognitive Decline in the Elderly AUC = area under the curve
(parametric analyses); PPV = positive predictive value; NPV=negative predictive value; LR=likelihood ratio.
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